Short answer
Voyager Therapeutics, Inc. (VYGR) filed its Q1 2026 10-Q quarterly report on May 7, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $3M (down 59.9% year over year) with net income of −$28M.
Q1 2026 key financials · XBRL
- Revenue
- $3M
- −59.9% YoY
- Net income
- −$28M
- +9.9% YoY
- Operating margin
- -1167.4%
- EPS (diluted)
- −$0.47
- +11.3% YoY
Source: XBRL data from the Voyager Therapeutics, Inc. (VYGR) Q1 2026 10-Q on SEC EDGAR. USD.
Voyager Therapeutics, Inc. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Net loss $27.9M for quarter ended March 31, 2026
- Accumulated deficit $473.8M as of March 31, 2026
- VY1706 IND process anticipated completion Q2 2026
- VY1706 clinical trial initiation expected second half 2026, subject to IND clearance
- Initial VY7523 tau-PET efficacy data expected second half 2026
Risk Factors
- No material changes disclosed; risks carried forward from the December 31, 2025 Form 10-K
- Regulatory and compliance exposure from U.S. federal securities laws governing insider trading
- Executive share-sale risk from Gregory Shiferman’s January 5, 2026 Rule 10b5-1 arrangement
- Equity dilution and liquidity risk from indeterminable RSU sell-to-cover transactions
- Clinical and competitive risks remain incorporated by reference from the 2025 Form 10-K
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Voyager Therapeutics, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.